Stonvex
Discover
  • Dashboard
  • World News
  • Stock News
  • Rankings
  • Quant Picks
  • Screener
Markets
  • Heatmap
  • Gainers & Losers
Tools
  • Compare
  • Calendar
  • Community
HomeRankingsScreenerPortfolioCommunity
Stonvex
Log inGet Started
← Back to search

ALNY

Live
Real-time chart · IB-grade AI research · Polygon.io data feed
Set alertSave
  • Overview
  • Financials
  • Filings
  • Short Interest
  • Ownership
  • Ratings
  • Peers
  • Options
  • News
✦
Stonvex AI

ALNY

AI Research Report

Powered by Claude

Ready to analyze ALNY

Runs the full IB-grade framework: Narrative, Reverse DCF, Comps, Sensitivity, and Deal Radar. Takes 20–40 seconds.

Free preview · 3 reports / hour · No sign-up required

Earnings

Next report date, year-over-year trend, and recent quarter history.

Earnings history activates with Polygon. When configured, this panel shows the next report date, consensus EPS/revenue, and the last 4 quarters of actual-vs-estimate.

Quant Grades

6-factor scoring with sector-relative rank. Updated daily.

Quant grades are available for tickers in our scored universe.

Financial statements

Most recent quarterly filings sourced directly from SEC EDGAR.

Financial statements activate with Polygon. The Developer plan includes quarterly and annual filings sourced directly from SEC EDGAR.

Corporate events

Share this analysis

Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.

Stonvex

AI-powered stock research for US equities.

hello@stonvex.com

Product

  • Rankings
  • Quant Picks
  • Screener
  • Markets
  • Compare
  • Calendar

Company

  • About Stonvex
  • Pricing & Plans
  • Community
  • Help & FAQ
  • Contact Us

Legal

  • Terms of Service
  • Privacy Policy
  • Privacy Consent
  • Disclaimer
  • Notices & Updates

© 2026 Stonvex. All rights reserved.

This site is for informational purposes only. Not investment advice. Past performance does not guarantee future results. Stonvex is not a registered investment advisor (RIA). You must be 18 years or older to use this service.

Latest news

Factor Grades

5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Biotechnology·NASDAQ NMS - GLOBAL MARKET·US·IPO 2004-05-28
📅 Earnings in 15d (Apr 30)
  • Benzinga·1d ago

    Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $505

    Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $515 to $505.

  • Yahoo·1d ago

    Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals

    Key opportunities in the oligonucleotide market include advancing therapeutics for rare and diverse diseases like neurodegenerative disorders and cancer, improving drug delivery systems, leveraging regulatory designations, and capitalizing on emerging RNA technologies to overcome existing therapy challenges.Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Oligonucleotides - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report delves into the realm of oligon

  • Yahoo·2d ago

    Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?

    ​Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the Best Growth Stocks to Buy With Highest Upside Potential. Wall Street has a positive view on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as 71% of the 28 analysts covering the stock have a Buy rating. Moreover, the 12-month median price target of the Street reflects more than 36.9% upside […]

  • Yahoo·5d ago

    Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025

    ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Large Cap Growth Strategy”. A copy of the letter can be downloaded here. Following the outbreak of the Middle East conflict, the market experienced a significant decline in growth stocks, resulting in substantial losses. In the quarter, the S&P 500 Index fell 4.3% […]

  • Yahoo·6d ago

    Alnylam Cardiovascular Data Highlights Potential Upside In ATTR-CM And Hypertension

    Alnylam Pharmaceuticals (NasdaqGS:ALNY) presented new clinical and real-world data on its cardiovascular RNAi portfolio at the American College of Cardiology’s Annual Scientific Session. The company highlighted durability and quality of life outcomes for vutrisiran in transthyretin-mediated amyloidosis, including ATTR-CM patients. Alnylam also reported new findings for zilebesiran in hypertension, focusing on high-risk patients. Alnylam focuses on RNA interference based medicines, and these...

  • View all news →

Analyst Consensus

Buy
Based on 36 analysts
Period: 2026-04-01
27 Buy (75%)9 Hold (25%)0 Sell (0%)
Rating Distribution
Strong Buy
7
Buy
20
Hold
9
Sell
0
Strong Sell
0
Trend
2026-04
27/9/0
2026-03
28/8/0
2026-02
27/9/0
2026-01
27/9/0
NASDAQ NMS - GLOBAL MARKETMarket closed
Alnylam Pharmaceuticals Inc
Biotechnology
$339.41
$6.41 (+1.92%)
Open
$330.81
Prev close
$333.00
Day range
$330.54 – $343.36
52W range
$214.76 – $495.55
Mkt cap
$45.01B
P/E
141.6
EPS
$2.25
Beta
0.37

Fundamentals

Valuation
Market Cap
$45.01B
P/E (TTM)
141.57S&P avg ~22
P/S (TTM)
11.96S&P avg ~2.8
P/B
66.57S&P avg ~4.5
P/FCF
74.95S&P avg ~26
EPS (TTM)
$2.25
Book/sh
$5.96
Cash/sh
$21.97
Profitability
Gross Margin
81.64%avg ~45%
Operating Margin
12.36%avg ~15%
Net Margin
8.45%avg ~12%
ROE
90.35%avg ~18%
ROA
6.75%avg ~7%
ROI
10.91%
Payout Ratio
—
FCF/sh
—
Growth & Health
Rev Growth YoY
65.19%
Rev Growth 5Y
49.77%
EPS Growth YoY
—
EPS Growth 5Y
—
Current Ratio
—
Quick Ratio
2.51
Debt/Equity
—
LT Debt/Eq
—
Trading & Dividends
Beta
0.37
52W High
$495.55
52W Low
$214.76
Avg Vol (10D)
1.05M
Avg Vol (3M)
1.42M
Div Yield
—
Div/sh (TTM)
—
Analyst
Buy (36)
Price Performance
5D+4.22%
MTD+0.64%
3M-16.62%
6M-26.33%
YTD-16.26%
1Y+47.16%

Factor Grades

View details →
C+
Overall score: 58/100
D-
Valuation
A+
Growth
B
Profitability
D+
Momentum
B
Financial Health

Recent insider activity

View all →
  • 4PRIMARY DOCUMENT
    8d ago
  • 4PRIMARY DOCUMENT
    Mar 6
  • 4PRIMARY DOCUMENT
    Mar 6
  • 4PRIMARY DOCUMENT
    Mar 6
  • 4PRIMARY DOCUMENT
    Mar 6